Skip to content

Study · Systematic review · 2026

14 results

Cardiovascular Outcomes in Adults With Type 2 Diabetes Treated With Tirzepatide: A Systematic Review and Meta-Analysis of Real-World Studies.

Kamrul-Hasan ABM, Chatterjee S, Ashraf H, Nagendra L, Dutta D, Pappachan JM

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists24 Nov 2025Cited by 2 (Europe PMC)

PMID41297885 (opens in a new tab)DOI10.1016/j.eprac.2025.11.010 (opens in a new tab)PepBankPUB-41297885
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes in real-world cohorts, tirzepatide reduced the risk of acute coronary syndrome versus control (HR 0.74).

    In plain wordsIn real-world studies of adults with type 2 diabetes, tirzepatide was linked to a lower risk of acute coronary syndrome than control.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAcute coronary syndrome versus control
    Study

    n: not reported in source

    Comparator
    Control group
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.74 ratio
    ACS
    95% CI
    0.62 to 0.89 ratio
    ACS

    Source sentences

    Summary
    ACS (HR 0.74 [0.62-0.89], P = .001)
    2 context sentences
    Summary · context
    Multiple databases and registries were searched for real-world observational studies involving individuals with T2D receiving tirzepatide.
    Summary · context
    Eight retrospective cohort studies (N = 118 252) were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes in real-world cohorts, tirzepatide reduced the risk of heart failure versus control (HR 0.65).

    In plain wordsIn real-world studies of adults with type 2 diabetes, tirzepatide was linked to a lower risk of heart failure than control.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHeart failure versus control
    Study

    n: not reported in source

    Comparator
    Control group
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.65 ratio
    HF
    95% CI
    0.53 to 0.82 ratio
    HF

    Source sentences

    Summary
    HF (HR 0.65 [0.53-0.82], P = .0002)
    2 context sentences
    Summary · context
    Multiple databases and registries were searched for real-world observational studies involving individuals with T2D receiving tirzepatide.
    Summary · context
    Eight retrospective cohort studies (N = 118 252) were included.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes in real-world cohorts, tirzepatide reduced the risk of stroke versus control (HR 0.71).

    In plain wordsIn real-world studies of adults with type 2 diabetes, tirzepatide was linked to a lower risk of stroke than control.

    Peptide
    Tirzepatide
    Outcome
    DecreaseStroke versus control
    Study

    n: not reported in source

    Comparator
    Control group
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.71 ratio
    stroke
    95% CI
    0.62 to 0.81 ratio
    stroke

    Source sentences

    Summary
    stroke (HR 0.71 [0.62-0.81], P < .00001)
    2 context sentences
    Summary · context
    Multiple databases and registries were searched for real-world observational studies involving individuals with T2D receiving tirzepatide.
    Summary · context
    Eight retrospective cohort studies (N = 118 252) were included.
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes in real-world cohorts, the risk of sudden cardiac death was similar between tirzepatide and control.

    In plain wordsIn real-world studies of adults with type 2 diabetes, the risk of sudden cardiac death was similar with tirzepatide and control.

    Peptide
    Tirzepatide
    Outcome
    No significant changeSudden cardiac death versus control
    Study

    n: not reported in source

    Comparator
    Control group
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, the risk of sudden cardiac death was similar between groups.
    2 context sentences
    Summary · context
    Multiple databases and registries were searched for real-world observational studies involving individuals with T2D receiving tirzepatide.
    Summary · context
    Eight retrospective cohort studies (N = 118 252) were included.
  5. 05HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes in real-world cohorts, the risk of acute coronary syndrome was similar between tirzepatide and semaglutide.

    In plain wordsIn real-world studies of adults with type 2 diabetes, the risk of acute coronary syndrome was similar with tirzepatide and semaglutide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAcute coronary syndrome versus semaglutide
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but similar risks for ACS, HF, sudden cardiac death, all-cause mortality, and composite outcomes.
    2 context sentences
    Summary · context
    Multiple databases and registries were searched for real-world observational studies involving individuals with T2D receiving tirzepatide.
    Summary · context
    Eight retrospective cohort studies (N = 118 252) were included.
  6. 06HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes in real-world cohorts, the risk of heart failure was similar between tirzepatide and semaglutide.

    In plain wordsIn real-world studies of adults with type 2 diabetes, the risk of heart failure was similar with tirzepatide and semaglutide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeHeart failure versus semaglutide
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but similar risks for ACS, HF, sudden cardiac death, all-cause mortality, and composite outcomes.
    2 context sentences
    Summary · context
    Multiple databases and registries were searched for real-world observational studies involving individuals with T2D receiving tirzepatide.
    Summary · context
    Eight retrospective cohort studies (N = 118 252) were included.
  7. 07HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes in real-world cohorts, the risk of sudden cardiac death was similar between tirzepatide and semaglutide.

    In plain wordsIn real-world studies of adults with type 2 diabetes, the risk of sudden cardiac death was similar with tirzepatide and semaglutide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeSudden cardiac death versus semaglutide
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but similar risks for ACS, HF, sudden cardiac death, all-cause mortality, and composite outcomes.
    2 context sentences
    Summary · context
    Multiple databases and registries were searched for real-world observational studies involving individuals with T2D receiving tirzepatide.
    Summary · context
    Eight retrospective cohort studies (N = 118 252) were included.
  8. 08HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes in real-world cohorts, tirzepatide reduced the risk of MACE versus control (HR 0.72).

    In plain wordsIn real-world studies of adults with type 2 diabetes, tirzepatide was linked to a lower risk of major cardiovascular events than control.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMajor adverse cardiovascular events versus control
    Study

    n: not reported in source

    Comparator
    Control group
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.72 ratio
    MACE
    95% CI
    0.6 to 0.86 ratio
    MACE

    Source sentences

    Summary
    MACE (HR 0.72 [0.60-0.86], P = .0004)
    2 context sentences
    Summary · context
    Multiple databases and registries were searched for real-world observational studies involving individuals with T2D receiving tirzepatide.
    Summary · context
    Eight retrospective cohort studies (N = 118 252) were included.
  9. 09HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes in real-world cohorts, tirzepatide reduced the risk of all-cause mortality versus control (HR 0.49).

    In plain wordsIn real-world studies of adults with type 2 diabetes, tirzepatide was linked to a lower risk of death from any cause than control.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAll-cause mortality versus control
    Study

    n: not reported in source

    Comparator
    Control group
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.49 ratio
    all-cause mortality
    95% CI
    0.37 to 0.67 ratio
    all-cause mortality

    Source sentences

    Summary
    all-cause mortality (HR 0.49 [0.37-0.67], P < .00001)
    2 context sentences
    Summary · context
    Multiple databases and registries were searched for real-world observational studies involving individuals with T2D receiving tirzepatide.
    Summary · context
    Eight retrospective cohort studies (N = 118 252) were included.
  10. 10HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes in real-world cohorts, tirzepatide lowered the risk of the composite of all-cause mortality plus cardiovascular outcomes versus control (HR 0.65).

    In plain wordsIn real-world studies of adults with type 2 diabetes, tirzepatide was linked to a lower risk of death or cardiovascular events than control.

    Peptide
    Tirzepatide
    Outcome
    DecreaseComposite of all-cause mortality plus cardiovascular outcomes versus control
    Study

    n: not reported in source

    Comparator
    Control group
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.65 ratio
    composite
    95% CI
    0.54 to 0.79 ratio
    composite

    Source sentences

    Summary
    The risk of composite outcomes of all-cause mortality plus CV outcomes was also lower with tirzepatide (HR 0.65 [0.54-0.79], P < .0001).
    2 context sentences
    Summary · context
    Multiple databases and registries were searched for real-world observational studies involving individuals with T2D receiving tirzepatide.
    Summary · context
    Eight retrospective cohort studies (N = 118 252) were included.
  11. 11HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes in real-world cohorts, tirzepatide had a lower risk of stroke than semaglutide.

    In plain wordsIn real-world studies of adults with type 2 diabetes, tirzepatide was linked to a lower risk of stroke than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseStroke versus semaglutide
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared to semaglutide, tirzepatide had lower risks of stroke and MACE
    2 context sentences
    Summary · context
    Multiple databases and registries were searched for real-world observational studies involving individuals with T2D receiving tirzepatide.
    Summary · context
    Eight retrospective cohort studies (N = 118 252) were included.
  12. 12HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes in real-world cohorts, tirzepatide had a lower risk of MACE than semaglutide.

    In plain wordsIn real-world studies of adults with type 2 diabetes, tirzepatide was linked to a lower risk of major cardiovascular events than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMajor adverse cardiovascular events versus semaglutide
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared to semaglutide, tirzepatide had lower risks of stroke and MACE
    2 context sentences
    Summary · context
    Multiple databases and registries were searched for real-world observational studies involving individuals with T2D receiving tirzepatide.
    Summary · context
    Eight retrospective cohort studies (N = 118 252) were included.
  13. 13HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes in real-world cohorts, the risk of all-cause mortality was similar between tirzepatide and semaglutide.

    In plain wordsIn real-world studies of adults with type 2 diabetes, the risk of death from any cause was similar with tirzepatide and semaglutide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAll-cause mortality versus semaglutide
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but similar risks for ACS, HF, sudden cardiac death, all-cause mortality, and composite outcomes.
    2 context sentences
    Summary · context
    Multiple databases and registries were searched for real-world observational studies involving individuals with T2D receiving tirzepatide.
    Summary · context
    Eight retrospective cohort studies (N = 118 252) were included.
  14. 14HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes in real-world cohorts, the risk of composite outcomes was similar between tirzepatide and semaglutide.

    In plain wordsIn real-world studies of adults with type 2 diabetes, the risk of the combined outcomes was similar with tirzepatide and semaglutide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeComposite outcomes versus semaglutide
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but similar risks for ACS, HF, sudden cardiac death, all-cause mortality, and composite outcomes.
    2 context sentences
    Summary · context
    Multiple databases and registries were searched for real-world observational studies involving individuals with T2D receiving tirzepatide.
    Summary · context
    Eight retrospective cohort studies (N = 118 252) were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.